<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-111497</identifier>
<setSpec>1576-1959</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of smoking habit in public health officials in 11 Primary Care Centers</dc:title>
<dc:description xml:lang="en">It is important to implement smoking cessation treatment in Primary Health Care (PHC). Thus, in the year 2010, we initiated a smoking cessation treatment program aimed at health care staff workers in this stage in 11 South-Eastern Metropolitan Health Services (SSMSO) and Viña-Quillota Health Services (SSVQ) out-patient clinics, in Chile. The intervention was based on professionals of respiratory disease programs, trained by a 106 hour internet and on-site course. The members of the health care site were interviewed. Smoking habit was analyzed by workshops, especially the contradictions between smoking and working in health care and psychosocial and pharmacological treatment was offered. A total of 796 health care workers were surveyed: Males-229 (28.8%). Smokers-332 (41.7%). Daily smokers-223 (28.0). High grade of addiction-25 (7.5%). A total of 81 staff workers received treatment, 76 receiving drugs. There was an average of 6.6 therapy sessions. The drugs were used in 3 regimens: bupropion 150 mg c/12, nicotine gum (2 mg) on demand and varenicline 1 mg c/12. Each center used only one regimen (at random) for 3 months. Secondary effects of the drugs were mild, 5.6%, and did not lead to treatment cessation. At 6 months, 29 staff workers (34.1%) continued without smoking. The cessation was verified by co-oximetry and witness information. Average treatment cost per person was $92 (USA). Conclusions. Treatment for smoking cessation in health care workers is possible, based on the staff workers of the PHC sites and with acceptable cost and performance. The project was funded by GlaxoSmithkline, PfizerChile, Johnson and Johnson Laboratories and the Health Care Services (AU)</dc:description>
<dc:creator>Villena, J</dc:creator>
<dc:creator>Medina, G</dc:creator>
<dc:creator>Ponce, R</dc:creator>
<dc:creator>Morales, M</dc:creator>
<dc:creator>Castillo, C</dc:creator>
<dc:creator>Pavié, J</dc:creator>
<dc:creator>Pozo, M. J</dc:creator>
<dc:creator>Véjar M, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Es importante implementar tratamiento de tabaquismo en la Atención Primaria de la Salud (APS). Por esta razón, en el año 2010 iniciamos en 11 consultorios de Servicios de Salud Metropolitano Suroriente (SSMSO) y Viña-Quillota (SSVQ), en Chile, un programa de tratamiento antitabáquico dirigido a funcionarios en esta etapa. La intervención estuvo basada en profesionales de programas de enfermedades respiratorias, capacitados mediante un curso internet-presencial de 106 h. Se encuestaron a los integrantes del centro de salud, se analizó tabaquismo mediante talleres, especialmente las contradicciones entre fumar y trabajar en la salud y se les ofreció tratamiento psicosocial y farmacológico. Un total de 796 funcionarios fueron encuestados. Varones, 229 (28,8%). Fumadores, 332 (41,7%). Fumadores diarios, 223 (28,0). Alto grado de adicción, 25 (7,5%). Ingresaron a tratamiento 81 funcionarios, reciben fármacos 76. El número de sesiones de terapia fue 6,6, promedio. Los fármacos se emplearon en 3 esquemas: bupropión 150 mg c/12, chicle de nicotina (2 mg) según demanda y vareniclina 1 mg c/12. Cada centro utilizó un solo tipo de esquema (al azar) por 3 meses. Efectos secundarios de fármacos fueron leves 5,6% y no determinaron suspensión de tratamiento. A los 6 meses, 29 funcionarios (34,1%) se mantenían sin fumar. La cesación fue comprobada por cooximetría e información de testigos. El costo del tratamiento promedio por persona fue US$92. Conclusión. Es posible realizar tratamiento de tabaquismo a los funcionarios de la salud, basado en profesionales de los centros APS con costo y rendimiento aceptable. El proyecto fue financiado por Laboratorios GlaxoSmithkline, PfizerChile, Johnson y Johnson y los Servicios de Salud (AU)</dc:description>
<dc:source>Prev. tab;15(1): 21-25, ene.-mar.2013. tab, ilus</dc:source>
<dc:identifier>ibc-111497</dc:identifier>
<dc:title xml:lang="es">Tratamiento de tabaquismo en funcionarios de la salud en 11 centros de Atención Primaria</dc:title>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d51528</dc:subject>
<dc:subject>^d13328</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d11756^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d23925^s22067</dc:subject>
<dc:subject>^d35120</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d30220^s22073</dc:subject>
<dc:subject>^d11756^s22045</dc:subject>
<dc:subject>^d8775^s22049</dc:subject>
<dc:subject>^d11756^s22066</dc:subject>
<dc:type>article</dc:type>
<dc:date>201303</dc:date>
</metadata>
</record>
</ibecs-document>
